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lations, or comparable study arms preventing a complete assessment of whether 
sub-indications of an anti-diabetic drug provided an “added benefit” to patients. 
Future clinical development plans should include well-designed comparative stud-
ies to improve likelihood of reimbursement and patient access.
PATIENT PREFERENCE STUDIES
PP1
PATIENTS’ AND PhySICIANS’ TImE TRADE-OFF PREFERENCES FOR ADvERSE 
OUTCOmES ASSOCIATED WITh mETASTATIC COlORECTAl CANCER 
TREATmENTS
Morlock R.1, Gonzalez J.M.2, Ogale S.1, Sommer N.1, Posner J.2, Grothey A.3
1Genentech, South San Francisco, CA, USA, 2RTI Health Solutions, Research Triangle Park, NC, 
USA, 3Mayo, Rochester, MN, USA
Objectives: To estimate health-state utilities for adverse outcomes associated 
with metastatic colorectal cancer. MethOds: Patients and physicians completed 
time trade-off (TTO) questions. Health states were drafted and refined based on 
literature review, and patient and clinician interviews. Four adverse conditions 
were described: severe papulopustular rash (rash), serious bleeding, severe heart 
attack, and gastrointestinal perforations. Respondents evaluated the risk of serious 
bleeding, heart attack, and gastrointestinal perforation. Three event risk levels were 
randomized across events and respondents. Rash was presented as a deterministic 
outcome, so respondents evaluated the impact of experiencing the rash, not as a 
‘risk’ of developing rash. Patients and physicians evaluated the health states in 
TTO questions that provided a range of time in the adverse health that would leave 
respondents indifferent between the adverse health states and shorter life spans 
with perfect health. TTO data were analyzed using an interval regression model to 
estimate the health-state utility for each side effect. Results were used to infer the 
health-state utility of the outcomes’ clinically relevant levels corresponding with 
the most commonly used targeted treatments for mCRC, VEGFi and EGFRi (20% 
chance of rash, 5% chance of serious hemorrhage, and a 2% chance of gastrointes-
tinal perforations and cardiopulmonary arrest). Results: A total of 127 patients 
and 150 physicians completed the TTO questions. Among clinically-relevant levels 
of the health states for patients, cardiopulmonary arrest had the lowest utility 
(0.68), with serious hemorrhage (0.74), GI perforation (0.79) and rash (0.91) hav-
ing higher levels of utility. Utility scores for physicians followed a similar pattern: 
cardiopulmonary arrest (0.75), serious hemorrhage (0.76), GI perforation (0.82) and 
rash (0.92). CONClUSIONS: Results add to previously published literature regarding 
utilities for adverse outcomes from patients’ and physicians’ perspectives. Results 
show that patient and physician ratings of health states were largely consistent, 
suggesting agreement in the perceived impact of these adverse events.
PP2
PATIENT PREFERENCES FOR FIRST-lINE mAINTENANCE TREATmENTS FOR 
OvARIAN CANCER
Mansfield C.A.1, Poulos C.1, Hackshaw M.D.2, Pugh A.1, Jobanputra M.H.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Philadelphia, PA, USA
Objectives: Elicit medicine preferences of women eligible to receive first-line 
maintenance treatment for ovarian cancer and estimate benefit-risk trade-
offs. MethOds: Women in the United States with self-reported physician diag-
noses of ovarian cancer and eligible for maintenance therapy completed an online 
discrete-choice experiment (DCE) survey. The survey presented nine choice ques-
tions, each including a pair of hypothetical medicine profiles with varying effi-
cacy, tolerability, and risks of side effects. Each profile was defined by the following 
attributes identified from the literature with clinical input and tested in patient 
interviews: progression-free survival (PFS), fatigue, diarrhea, nausea and vomiting, 
hypertension, and risk of gastrointestinal (GI) perforation. The profiles in the choice 
questions were based on an experimental design with known statistical properties. 
Random-parameters logit was used to estimate preferences. Results: Two hundred 
women completed the survey; median age was 49 years, 26% were late stage (3/4), 
and 44% had been diagnosed within 2 years. Across the attributes, better outcomes 
were significantly preferred to worse outcomes, except that respondents did not 
distinguish between no nausea and mild nausea. Relative to the other attributes 
and levels, respondents placed the greatest weight on avoiding severe diarrhea, 
followed by reducing the risk of GI perforation, and increased PFS. Respondents 
were willing to give up 6.5 months of PFS to reduce diarrhea from severe to none. 
No statistical differences were found between the overall preferences of early versus 
late stage respondents, respondents above and below the median age in the sample, 
and respondents who had been diagnosed in the last 2 years compared to those 
diagnosed more than 2 years ago. cOnclusiOns: Women with ovarian cancer were 
willing to trade-off efficacy (PFS) for improvements in side effects and risk. The lack 
of differences across subgroups suggest consistent preferences across the attributes 
within our sample. Funded by GSK.
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PATIENT vERSUS GENERAl POPUlATION PREFERENCES IN ANTICOAGUlANT 
ThERAPy
Najafzadeh M., Gagne J.J., Choudhry N.K., Polinski J., Avorn J.L., Schneeweiss S.
Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Objectives: Relative preference weights for outcomes of anticoagulant therapy 
can be used to inform quantitative benefit-risk analyses. Whether patients with 
cardiovascular diseases (CVD) and the general population have different preferences 
for benefits and risks of anticoagulant therapy is unknown. Using a Discrete Choice 
Experiment (DCE), we elicited and compared anticoagulant treatment outcomes 
preferences between patients and the general population. MethOds: A sample of 
patients with CVD and a general US population sample were selected from online 
panels. A DCE questionnaire was designed and administered to elicit preferences 
for benefits and risks. Seven attributes described hypothetical treatments randomly 
hT2
APPlICATION OF COST-EFFECTIvENESS lOGIC TO US mANAGED CARE DRUG 
FORmUlARIES: lONG TERm OUTCOmES OF A vAlUE-BASED FORmUlARy
Yeung K1, Basu A2, Hansen RN1, Watkins J3, Sullivan SD2
1School of Pharmacy, University of Washington, Seattle, WA, USA, 2University of Washington, 
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Objectives: Cost-effectiveness analysis (CEA) is explicitly used for informing drug 
coverage decisions in many countries but not in the United States. Evidence suggests 
that failure to incorporate value considerations in coverage decisions may lead to 
reduced economic efficiency in the form of increased costs or worsened health 
outcomes. Yet the use of CEA in the context of binary coverage decisions (yes or 
no) may not be politically or socially feasible in the US. In 2010, Premera Blue Cross 
implemented a value-based formulary (VBF) that uses CEA to determine the copay-
ment level-not binary coverage-for each drug in the formulary; drugs with lower 
incremental cost-effectiveness ratios (ICERs) are assigned lower copayments, drugs 
with higher ICERs are assigned higher copayments. The objective of this study is to 
assess the impact of Premera’s VBF on healthcare costs and outcomes. MethOds: 
We utilize an interrupted time series design with concurrent control group in order 
to examine the impact of the VBF on both pharmacy and medical costs for enrollees 
and the health plan separately and to examine the impact of the VBF on both emer-
gency department visits and acute hospitalizations. In order to accomplish these 
aims, we utilize segmented regression models with two-part generalized estimating 
equations for analysis. Results: Preliminary descriptive analysis suggests that over 
the 4 years of observation, comparing the period before VBF implementation to the 
period after VBF implementation, both medical and pharmacy costs increased more 
in the control group ($38.37 and $4.79 per member per month (PMPM)) than in the 
VBF group ($3.16 and -$0.54 PMPM). The number of emergency department visits and 
acute hospitalizations did not change in either group. cOnclusiOns: Preliminary 
analyses suggest that the use of cost-effectiveness principles in the US context may 
lead to greater economic efficiency. Subsequent analyses utilizing greater control for 
confounding will establish more valid estimates of outcomes and costs.
hT3
ANAlySIS OF NICE DRUG TEChNOlOGy APPRAISAlS (2001-SEPTEmBER 2014)
Briceno V, Seoane-Vazquez E
MCPHS University, Boston, MA, USA
Objectives: The UK National Institute for Health and Care Excellence (NICE) pro-
vides guidance and advice to improve health care in the UK. This study assessed 
the NICE Drug Technology Appraisals published in the period 2001-September 
2014. MethOds: The list of NICE guidance, including published guidance, in 
development and consultations was extracted from NICE webpage. Descriptive 
statistics and chi-square were used in the analysis. Results: In September 2014, 
NICE listed 994 guidance documents, including 246 technology appraisals (TA), of 
which 207 were drug TA. The drug TA assessed 158 different drugs, combinations, 
or drug classes. 75.8% of the drug TA evaluated was recommended by NICE in the 
National Health Service (NHS), however 17.0% of them were not recommended. NICE 
was unable to recommend them because no evidence submission was received 
from the drug sponsor in 7.2% of the TA. In 46.2% of the 91 TA published in 2010-
Sep 2014 and recommended by NICE, the sponsor agreed a patient access scheme 
with the Department of Health to provide a confidential discount. The percent-
age of TA resulting in drugs with indications recommended by NICE decreased 
over time from 89.5% (n= 49) in 2001-2004, to 71.7% (n= 91) in 2005-2009, and 75.8% 
in 2010-September 2014 (p< 0.001). There were six therapeutic classes with 10 or 
more TA: Cancer (68 TA, 57.4% recommended by NICE), blood and immune sys-
tem conditions (27, 77.8%), cardiovascular conditions (20, 95.0%), musculoskele-
tal conditions (16, 81.3%), infections (11, 90.9%), and neurological conditions (10, 
90.0%). cOnclusiOns: Most of the TA resulted in a positive recommendation by 
NICE for using the drug in the NHS. Oncology and blood and immune system condi-
tion had the lowest percentage of TA resulting in a positive evaluation from NICE. 
Over 45% of the TA published after 2010 resulted in a confidential discount provided 
by the sponsor company to the NHS.
hT4
IqWIG EARly BENEFIT ASSESSmENTS OF TyPE 2 DIABETES ThERAPIES
Oehrlein EM, Hanna ML, Perfetto EM
University of Maryland, School of Pharmacy, Baltimore, MD, USA
Objectives: Since 2011, the Institute for Quality and Efficiency in Health Care 
(IQWiG) has awarded very few anti-diabetic therapies an “added benefit” over 
current standard therapies status. IQWiG dossier evaluations were examined to 
determine if new therapies do not demonstrate “added benefit” or if results may 
be due to a lack of comparative evidence. MethOds: Results from IQWiG dossier 
assessments for all anti-diabetic drug therapies requiring early benefit assessment 
were examined. IQWiG’s website was searched for “diabetes,” identifying Albiglutide, 
Canagliflozin, Dapagliflozin, Empagliflozine, Linagliptin, Lixisenatide, Saxagliptin, 
Sitagliptin, and Vildagliptin. Dossier assessment results were reviewed for all sub-
indications to determine if added benefit had been evaluated. Results: In total, 14 
dossier assessments (9 monotherapies; 5 combination therapies) were reviewed rep-
resenting a total of 48 sub-indications. Of the 48 sub-indications, 2 were designated 
as having “added benefit” or “hint of added benefit,” the remaining 46 did not. The 
most common reasons for no evidence of “added benefit” were: no evidence sub-
mitted (n= 13) or evidence deemed irrelevant (n= 33). The most common reasons for 
supporting studies being deemed irrelevant included: differing “therapeutic strate-
gies” in study arms (n= 4); deviation from G-BA recommended comparator (n= 6); 
lack of power to demonstrate added benefit (n= 1); non-compliance with approved 
dosage (n= 12); non-compliance with approved population (n= 12); insulin therapy 
not tailored to patient (n= 6); study duration too short (n= 5). cOnclusiOns: In most 
cases, the evidence needed to perform an IQWiG early benefit assessment for drug 
therapies for Type II Diabetes did not exist. Moreover, studies with the potential to 
provide the appropriate evidence lacked use of approved dosage, indicated popu-
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diabetes researchers who need to classify patients’ renal impairment stage in the 
absence of detailed eGFR data.
PRm2
COmPARISON OF IRRITABlE BOWEl SyNDROmE WITh CONSTIPATION 
AND ChRONIC CONSTIPATION PATIENT IDENTIFICATION UTIlIzING 
ADmINISTRATIvE ClAImS-BASED AlGORIThmS, mODIFIED ROmE III 
DIAGNOSTIC CRITERIA, AND PATIENT-REPORTED PhySICIAN DIAGNOSES
Buono J.L.1, Stephenson J.J.2, Spalding W.M.3, Cai Q.2, Tan H.2, Carson R.T.1, Doshi J.A.4
1Forest Research Institute, Inc., a subsidiary of Actavis plc, Jersey City, NJ, USA, 2HealthCore Inc., 
Wilmington, DE, USA, 3Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, 4University of 
Pennsylvania, Philadelphia, PA, USA
Objectives: Given the lack of specific ICD-9 codes, no definitive method exists for 
identifying irritable bowel syndrome with constipation (IBS-C) and chronic constipa-
tion (CC) patients in administrative claims. This study compared patients identified 
as having IBS-C and CC through claims-based algorithms with modified Rome III 
criteria and patient-reported physician diagnoses. MethOds: Consenting patients 
aged ≥ 18 years identified from the HealthCore Integrated Research Database as 
having IBS-C (≥ 1 IBS claim and ≥ 2 constipation claims or ≥ 1 constipation claim 
and ≥ 1 constipation-related pharmacy claim) or CC (≥ 2 constipation claims ≥ 90 
days apart or ≥ 1 constipation claim and ≥ 1 constipation-related pharmacy claim 
≥ 90 days apart and no IBS claims) completed a cross-sectional survey that included 
questions pertaining to IBS-C/CC symptoms based on modified Rome III criteria and 
patient self-report of IBS-C and CC physician diagnoses to confirm claims-based 
diagnoses. Results: Among 236 claims-based IBS-C patients, 22% met Rome III 
IBS-C criteria and 43% reported being told by a physician they had IBS-C. In addi-
tion, 33% of claims-based IBS-C patients reported being told by a physician they 
had CC. Among 456 claims-based CC patients, 27% met Rome III CC criteria and 39% 
reported being told by a physician they had CC. However, 38% of claims-based CC 
patients met Rome III criteria for IBS-C and 18% reported being told they had IBS-C. 
Patients who did and did not meet Rome III criteria had similar demographic and 
clinical characteristics. cOnclusiOns: A majority of patients identified as having 
IBS-C and CC via claims did not meet Rome III criteria. There was greater agreement 
between claims-based criteria and patient-reported physician diagnoses than Rome 
criteria. Our findings suggest that patients identified through claims may have been 
asymptomatic at the time of the survey, and those identified as CC patients may be 
IBS-C patients who never received an IBS claim.
PRm3
PSyChOmETRIC vAlIDATION OF PERFORmANCE OUTCOmES (PERFOS) FOR USE 
WITh hIP FRACTURE (hF) POPUlATIONS
Gentile B.1, Ballinger R.S.2, Doll H.A.2, Bush E.N.3
1ICON, San Francisco, CA, USA, 2ICON, Oxford, UK, 3Eli Lilly, Indianapolis, IN, USA
Objectives: The measurement properties of three PerfOs [Timed Up-and-Go (TUG), 
4-Step Stair Climb (4SC) and Repeated Chair Stands (RCS, in two versions with arms 
folded, RCS-A, or arm rests, RCS-B)] were evaluated in hip fracture (HF) surgery 
patients. MethOds: Patients were recruited from 11 clinical sites across 6 US states. 
Participants visited sites at designated time points after HF surgery when patient 
reported outcome (PRO) measures, patient- and clinician-reported global concept 
items (GCI), and PerfOs were administered. PerfOs were scored as time (seconds, s) 
to complete each test. PerfO measurement properties evaluated included: reliability 
(inter-rater, test-retest), construct validity (known-groups, convergent/divergent), 
ability to detect change, minimal important difference (MID) and responder defi-
nitions. Results: Data were recruited from 75 patients (mean age 79.64, SD 6.83 
years; 68.0% female) at baseline; from 68 and 66 at visits 2 and 3. Inter-rater (ICCs: 
0.87 to 0.97) and test-retest (ICCs: 0.91-0.95) reliability was excellent across the 
PerfOs. Known-groups validity: Those without an assistive device had quicker mean 
completion times for all PerfOs but the RCS-A. In addition, TUG times were shorter 
for patients with high versus low SF-12 physical component summary (PCS) scores 
(p = .009). Convergent/divergent validity: the TUG, RCS-B, and 4SC demonstrated 
moderate correlations with the SF-12 PCS (rs ranged -0.227 to -0.449), and stronger 
correlations with the individual physical dimensions than the mental component 
(MCS) and dimension scores. Ability to detect change: patients demonstrated sig-
nificant changes in PerfOs from baseline to Visit 2 for the RCS-B (p = 0.030) and 4SC 
(p = 0.034). MIDs ranging from 1.5s (4SC) to 6.0s (TUG) were found. Based on Best 
Cut Points (BCP) of one-point change in clinician GCIs and values of minimal detect-
able change (MDC90), responder definitions between 2.0s (4SC) and 3.5s (TUG) are 
recommended. cOnclusiOns: Overall, the three PerfOs demonstrated adequate 
psychometric properties.
PRm4
GETTING ThE FUll PICTURE: ThE ImPORTANCE OF ExRAPOlATING BEyOND 
ThE DATA
Al-Mutairi R., Rittenhouse B.
MCPHS University, Boston, MA, USA
Objectives: Clinical assessments with a limited time horizon for data collection 
are typical. One example is a (now dated) 10-year study of statin therapy by Pharaoh 
& Hollingsworth, 1996 (P & H). Gray (2011) suggests that this study likely under-
estimates the effect of the intervention by limiting its time horizon. We explore 
this suggestion as a methodological point. MethOds: Using life table methods we 
analyzed one cohort from the P & H publication for which data were reported suffi-
ciently (50-year old men with pre-existing CHD) and compared their limited horizon 
analysis with one which extrapolates until the cohort lives out its life expectancy 
under each treatment alternative. Because of the lack of longer term data, assump-
tions need to be employed in order to extend the results (e.g. the treatment effect 
persists, fully, partially, at different levels, or not at all). Results: We replicated the 
P & H 10-year horizon that indicated a treatment/no treatment mean life expectancy 
difference of 0.071 life years (LYs). Assuming a fully persistent treatment effect over 
lifetimes, this increased to 2.35 LYs in the extrapolation, clearly sufficiently differ-
labeled “new drug,” “old drug,” or “no drug”: non-fatal stroke, non-fatal myocar-
dial infarction (MI), cardiovascular death, minor bleeding, major bleeding, bleeding 
death, and need for therapeutic monitoring. We estimated preference weights and 
maximum acceptable risks. Results: A total of 341 patients and 352 individuals 
from the general population completed the questionnaire. On average, patients per-
ceived a 1% increased risk of a fatal bleeding equivalent to a 2% increase in non-fatal 
MI, a 3% increase in non-fatal stroke, a 3% increase in cardiovascular death, a 6% 
increase in major bleeding, or a 16% increase in minor bleeding. As compared to the 
patients, the general population had similar preferences except that they perceived 
a 3% increase in non-fatal MI or a 13% increase in minor bleeding equivalent to a 
1% increase in risk of bleeding death. Patients were less likely to choose “no drug” 
(odds ratio, 0.72; 95% confidence interval, 0.61- 0.84) or “old drug” (odds ratio, 0.86; 
95% confidence interval, 0.81-0.93) than “new drug.” The general population sample 
was indifferent to the drug labels. cOnclusiOns: Patients and the general popu-
lation had similar relative preferences for anticoagulant treatment outcomes but 
were more likely to choose “new drug,” irrespective of its relative benefits and risks.
PP4
mEASURING TREATmENT PREFERENCES OF PATIENTS DIAGNOSED WITh 
IDIOPAThIC PUlmONARy FIBROSIS USING BEST-WORST SCAlING
Camponeschi G.F.1, Bridges J.F.2, Danoff S.K.1, Richardson B.1
1Johns Hopkins University, Baltimore, MD, USA, 2John Hopkins Bloomberg School of Public Health, 
Baltimore, MD, USA
Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare, degenerative disease. 
While recently approved therapies provide hope, research is needed to assess 
the value of treatment benefits and risks. This study sought to develop and test 
a patient-centered survey instrument to value the benefits and risks of IPF thera-
pies. MethOds: Using patient and stakeholder engagement, researchers developed 
a survey instrument for measuring the treatment preferences of IPF patients. This 
led to developing a novel best-worst scaling instrument to assess six treatment 
attributes, each defined across three levels, including lung function, shortness of 
breath, persistent cough, gastrointestinal problems, skin problems and risk of liver 
toxicity. Surveys were completed in person or by mail. Patients were shown 18 treat-
ment profiles, created through a main-effect orthogonal experimental design, and 
asked to identify the best and worst aspect of each treatment. Preference weights 
were estimated using a simple score consisting of the number of times a level was 
chosen as best minus the number of times it was chosen as worst and divided by 
the total number of times the level was shown. Conditional on the level chosen in 
the experiment, attribute importance was estimated by comparing the range of 
scores across each attribute, relative to all such deviations. Results: Thirty-five 
participants completed the survey. The most important attribute preferred was 
effect on lung function (35%), followed by risk of gastrointestinal problems (23%), 
risk of liver toxicity (12%) and impact on persistent cough (11%). Patients estimated 
the least important attributes to be risk of skin problems (9%) and impact on short-
ness of breath (9%). cOnclusiOns: This research demonstrates the merits of a 
community-centered approach to survey instrument development to measure 
preferences and illustrates the value in quantifying preferences. Further research 
is needed to assess the generalizability of these findings and the implications for 
decision making.
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DEvElOPmENT AND vAlIDATION OF A U.S. ADmINISTRATIvE ClAImS-BASED 
AlGORIThm TO ClASSIFy PATIENTS WITh TyPE 2 DIABETES mEllITUS INTO 
RENAl ImPAIRmENT STAGES
Johnston S.1, Sheehan J.2, Riehle E.1, Cappell K.A.3, Varker H1, Anzalone D4, Ghannam A2, 
Kalsekar I4
1Truven Health Analytics, Bethesda, MD, USA, 2AstraZeneca, Fort Washington, PA, USA, 3Truven 
Health Analytics, Ann Arbor, MI, USA, 4AstraZeneca, Wilmington, DE, USA
Objectives: The validity of diagnosis/procedure coding for determining the severity 
of renal impairment is unknown. This retrospective, observational study developed 
an administrative claims-based algorithm which classified patients with type 2 
diabetes mellitus (T2DM) into renal impairment stages using estimated glomerular 
filtration rate/1.73 sq M by MDRD equation (eGFR) as the measure for renal func-
tion. MethOds: The data source was U.S. administrative claims collected from 
among a sample of 35,624 patients ≥ 18 years of age who, during the period from 
1/1/2012-12/31/2012, had ≥ 1 laboratory result for eGFR, ≥ 2 medical claims with a 
diagnosis code for T2DM, continuous insurance enrollment, and no medical claims 
with a diagnosis/procedure code for type 1 diabetes, gestational diabetes, or preg-
nancy. The sample was divided into two equal random samples: a test set and 
validation set. Among the test set, four logistic regressions were fit modeling Kidney 
Disease Outcomes Quality Initiative-defined renal impairment stages (eGFR < 15, 
< 30, < 60, and < 90) as a function of age, sex, and 25 binary indicators for the presence 
of medical claims with renal impairment-related diagnosis/procedure codes. From 
each regression, a predicted probability was obtained for the validation set and per-
formance of the algorithm was tested (e.g., by ROC analysis) at varying probability 
cutoff classification thresholds. Results: In the validation set, the percentage of 
patients correctly classified by the test set algorithm using a standard probability 
cutoff= 0.5 was 75.9% for eGFR < 90, 82.1% for < 60, 97.3% < 30, and 99.3% for < 15; 
in the test set, these same percentages deviated by less than 1 percentage point. 
Model C-statistics ranged from 0.79 for eGFR < 90 to 0.89 for eGFR < 15. Sensitivity/
specificity varied considerably by selected probability cutoffs. cOnclusiOns: This 
novel, replicable, administrative claims-based algorithm should prove useful to 
